Thread by @DavidLeverenz

How well did the #RheumRibbonPanel match #RheumMadness participants' predictions in the #SeronegativeSixteen?

Belimumab for LN vs. Anifrolumab

👩‍⚖️Panel:
Belimumab for LN: 5
Anifrolumab: 2

👩‍💻Participants:
80% picked belimumab for LN

More in 🧵 below 👇 (1/8)

PEXIVAS vs. Avacopan

👩‍⚖️Panel:
PEXIVAS: 3
Avacopan: 4

👩‍💻Participants:
66% picked avacopan

(2/8)

IgG4-RD Classification Criteria vs. RP Subtypes

👩‍⚖️Panel:
IgG4-RD Classification Criteria: 5
RP Subtypes: 2

👩‍💻Participants:
77% picked IgG4-RD Classification Criteria

(3/8)

Anti-CD38 in Refractory SLE vs. VEXAS

👩‍⚖️Panel:
Anti-CD38 in Refractory SLE: 2
VEXAS: 5

👩‍💻Participants:
83% picked VEXAS

(4/8)

SEMIRA vs. Harms of Short Term Steroids

👩‍⚖️Panel:
SEMIRA: 4
Harms of Short Term Steroids: 3

👩‍💻Participants:
53% picked SEMIRA

(5/8)

UK FROST vs. PT/GC Injection for Knee OA

👩‍⚖️Panel:
UK FROST: 3
PT/GC Injection for Knee OA: 4

👩‍💻Participants:
77% picked PT/GC Injection for Knee OA

(6/8)

PRIME Cells vs. Synovial B Cells & Therapy Response (R4RA)

👩‍⚖️Panel:
PRIME Cells: 4
R4RA: 3

👩‍💻Participants:
61% picked PRIME Cells

(7/8)

FAST Study vs. ACR Gout Guidelines

👩‍⚖️Panel:
FAST Study: 4
Gout Guidelines: 3

👩‍💻Participants:
55% picked FAST

(8/8)

@threadreaderapp please unroll